Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.

Preskorn SH.

J Psychiatr Pract. 2019 Jul;25(4):290-297. doi: 10.1097/PRA.0000000000000399.

PMID:
31291209
2.

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).

Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB.

Int J Neuropsychopharmacol. 2019 Jul 10. pii: pyz039. doi: 10.1093/ijnp/pyz039. [Epub ahead of print]

PMID:
31290965
3.
4.

Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?

Goldberg JF, Rosenblat JD, McIntyre RS, Preskorn SH, de Leon J.

J Psychiatr Res. 2019 Jul;114:208-209. doi: 10.1016/j.jpsychires.2019.04.002. Epub 2019 Apr 5. No abstract available.

PMID:
31064655
6.

Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.

Preskorn SH.

J Psychiatr Pract. 2019 Jan;25(1):34-40. doi: 10.1097/PRA.0000000000000362.

PMID:
30633730
7.

Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.

Preskorn SH.

Handb Exp Pharmacol. 2019;250:307-324. doi: 10.1007/164_2018_169.

PMID:
30570691
8.

Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study.

Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB.

Schizophr Res. 2019 Apr;206:291-299. doi: 10.1016/j.schres.2018.11.002. Epub 2018 Nov 23.

PMID:
30478008
9.

Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.

Preskorn SH.

J Psychiatr Pract. 2018 Sep;24(5):341-347. doi: 10.1097/PRA.0000000000000335.

PMID:
30427821
10.

Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.

Preskorn SH.

J Psychiatr Pract. 2018 Jul;24(4):261-268. doi: 10.1097/PRA.0000000000000322.

PMID:
30427809
11.

Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.

Macaluso M, Preskorn SH.

J Psychiatr Pract. 2018 Nov;24(6):416-419. doi: 10.1097/PRA.0000000000000345.

PMID:
30395549
12.
13.

Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.

Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH.

Transl Psychiatry. 2018 Jan 24;8(1):27. doi: 10.1038/s41398-017-0073-7.

14.

CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.

Preskorn SH.

J Psychiatr Pract. 2017 Nov;23(6):425-430. doi: 10.1097/PRA.0000000000000274.

PMID:
29303950
15.
16.

Switching From the Oral to the Depot Formulation of a Medication: Clinically Relevant Pharmacokinetic Concepts and Considerations.

Preskorn SH.

J Psychiatr Pract. 2017 May;23(3):200-209. doi: 10.1097/PRA.0000000000000236.

PMID:
28492458
17.

Tardive Dyskinesia: A Historical Perspective.

Macaluso M, Flynn A, Preskorn SH.

J Psychiatr Pract. 2017 Mar;23(2):121-129. doi: 10.1097/PRA.0000000000000224. Review.

PMID:
28291037
18.

Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome.

Preskorn SH.

J Psychiatr Pract. 2017 Jan;23(1):44-48. doi: 10.1097/PRA.0000000000000207.

PMID:
28072644
20.

National Initiative to Prevent Suicide (NIPS): A New Proposal to Improve the Understanding and Prevention of Suicide.

Preskorn SH.

J Psychiatr Pract. 2016 Sep;22(5):398-404. doi: 10.1097/PRA.0000000000000183.

PMID:
27648504
21.

New Laboratory Tests in Psychiatry: What Should Mental Health Practitioners Know?

Preskorn SH.

J Psychiatr Pract. 2016 Jul;22(4):308-12. doi: 10.1097/PRA.0000000000000165. Review.

PMID:
27427842
22.

Personalized Medicine in Psychiatry: Concepts for Bringing Associated Testing Into Clinical Practice.

Preskorn SH.

Mayo Clin Proc. 2016 Jul;91(7):827-9. doi: 10.1016/j.mayocp.2016.05.011. Epub 2016 Jun 21. No abstract available.

PMID:
27289412
23.

The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli.

Young KD, Preskorn SH, Victor T, Misaki M, Bodurka J, Drevets WC.

Int J Neuropsychopharmacol. 2016 Sep 21;19(9). pii: pyw036. doi: 10.1093/ijnp/pyw036. Print 2016 Sep.

24.
25.

High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia.

Wehler CA, Preskorn SH.

J Clin Psychiatry. 2016 Apr;77(4):e451-6. doi: 10.4088/JCP.14m09686.

PMID:
27137429
26.
28.

Amygdala activity during autobiographical memory recall as a biomarker for residual symptoms in patients remitted from depression.

Young KD, Drevets WC, Bodurka J, Preskorn SS.

Psychiatry Res Neuroimaging. 2016 Feb 28;248:159-61. doi: 10.1016/j.pscychresns.2016.01.017. Epub 2016 Jan 18.

PMID:
26809279
29.

A Way of Conceptualizing Benzodiazepines to Guide Clinical Use.

Preskorn SH.

J Psychiatr Pract. 2015 Nov;21(6):436-41. doi: 10.1097/PRA.0000000000000114.

PMID:
26554326
30.

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

Macaluso M, Nichols AI, Preskorn SH.

Prim Care Companion CNS Disord. 2015 Mar 19;17(2). doi: 10.4088/PCC.14r01710. eCollection 2015.

31.

Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

Preskorn S, Flynn A, Macaluso M.

J Psychiatr Pract. 2015 Sep;21(5):359-69. doi: 10.1097/PRA.0000000000000101. Review.

PMID:
26348804
32.

How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.

Macaluso M, Kazanchi H, Preskorn SH.

Expert Opin Drug Metab Toxicol. 2015;11(8):1317-27. doi: 10.1517/17425255.2015.1059821. Review.

PMID:
26173973
33.

How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment.

Preskorn SH, Macaluso M, Trivedi M.

J Psychiatr Pract. 2015 Jul;21(4):267-74. doi: 10.1097/PRA.0000000000000082.

PMID:
26164052
34.

Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group.

J Psychiatr Pract. 2015 Mar;21(2):140-9. doi: 10.1097/01.pra.0000462606.17725.93.

PMID:
25782764
35.
36.

CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.

Preskorn SH.

J Psychiatr Pract. 2015 Jan;21(1):60-6. doi: 10.1097/01.pra.0000460622.33300.64. Review.

PMID:
25603452
37.

CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.

Preskorn SH.

J Psychiatr Pract. 2014 Nov;20(6):460-5. doi: 10.1097/01.pra.0000456594.66363.6f.

PMID:
25406050
38.

Clinical psychopharmacology and medical malpractice: the four Ds.

Preskorn SH.

J Psychiatr Pract. 2014 Sep;20(5):363-8. doi: 10.1097/01.pra.0000454781.67482.ad. Review.

PMID:
25226197
39.

The package insert: who writes it and why, what are its implications, and how well does medical school explain it?

McMahon D, Preskorn SH.

J Psychiatr Pract. 2014 Jul;20(4):284-90. doi: 10.1097/01.pra.0000452565.83039.20. Erratum in: J Psychiatr Pract. 2014 Sep;20(5):369.

PMID:
25036584
40.

Lurasidone drug-drug interaction studies: a comprehensive review.

Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A.

Drug Metabol Drug Interact. 2014;29(3):191-202. doi: 10.1515/dmdi-2014-0005. Review.

PMID:
24825095
41.
42.

Clinical pharmacology in the development of new antidepressants: the challenges.

Alexander RC, Preskorn S.

Curr Opin Pharmacol. 2014 Feb;14:6-10. doi: 10.1016/j.coph.2013.09.016. Epub 2013 Oct 19. Review.

PMID:
24565005
43.

The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example.

Preskorn SH.

J Psychiatr Pract. 2014 Jan;20(1):59-60. doi: 10.1097/01.pra.0000442938.61575.c2.

PMID:
24419310
44.

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.

Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC.

J Psychiatr Pract. 2014 Jan;20(1):12-24. doi: 10.1097/01.pra.0000442935.15833.c5.

PMID:
24419307
45.

Outliers on the dose-response curve: if the problem is not concentration, then what?

Preskorn SH.

J Psychiatr Pract. 2013 Nov;19(6):490-4. doi: 10.1097/01.pra.0000438188.66735.68. Review.

PMID:
24241502
46.

Dr Preskorn replies.

Preskorn SH.

J Clin Psychiatry. 2013 Oct;74(10):1025-6. doi: 10.4088/JCP.13flr08555a. No abstract available.

PMID:
24229758
48.

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.

Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A.

Hum Psychopharmacol. 2013 Sep;28(5):495-505. doi: 10.1002/hup.2338.

PMID:
24014143
49.

Neuroscientific basis of corticosteroid-induced changes in human cognitive and emotional processing: implications for affective illness.

Young KD, Preskorn SH.

J Psychiatr Pract. 2013 Jul;19(4):309-15. doi: 10.1097/01.pra.0000432601.09514.12. Review.

PMID:
23852106
50.

Declining differences in response rates with antidepressants versus placebo: a modest proposal for another contributing cause.

Preskorn SH.

J Psychiatr Pract. 2013 May;19(3):227-33. doi: 10.1097/01.pra.0000430506.37144.d1. Review.

PMID:
23653079

Supplemental Content

Loading ...
Support Center